Clinical effect of self-made Jiuxin decoction in the treatment of end-stage hypertrophic non-obstructive cardiomyopathy / 中国基层医药

ABSTRACT

Objective@#To observe the clinical effect of self-made Jiuxin decoction in the treatment of end-stage hypertrophic non-obstructive cardiomyopathy.@*Methods@#From July 2016 to October 2017, 60 patients with end-stage hypertrophic non-obstructive cardiomyopathy in the First People′s Hospital of Yuhang District were randomly divided into two groups according to digital table, with 30 cases in each group.The control group was treated with conventional western medicine, and the observation group was treated with self-made Jiuxin soup for a week.The changes of body weight, degree of edema, NYHA class, Lee score, B-type natriuretic peptide, blood angiotensin Ⅱ, blood potassium, sodium, chlorine content and other indicators before and after treatment were observed in the two groups.@*Results@#After one-week treatment, the cardiac function and heart failure indicators of the two groups were all significantly improved(the observation group t=10.527, 15.358, all P<0.01; the control group t=7.504, 12.417, all P<0.01), and the indicators of the observation group were better than those of the control group, and the differences between the two groups were statistically significant(t=3.772, 4.446, all P<0.01). After treatment, the levels of B-type natriuretic peptide of the two groups were significantly lower than those before treatment (the observation group t=5.628, the control group t=11.423, all P<0.05). The angiotensin and renin levels in the observation group were all significantly lower than those before treatment(t=4.355, 6.418, all P<0.05), and the indicators of the observation group were all significantly lower than those of the control group(t=3.521, 4.275, all P<0.05). The incidence rate of adverse reaction of the observation group was significantly lower than that of the control group(3.3% vs.23.3%, χ2=5.192, P=0.023).@*Conclusion@#Self-made Jiuxin decoction can significantly improve the cardiac function in patients with end-stage hypertrophic non-obstructive cardiomyopathy and it is a safe way of treatment.